focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-Time to start some defensive rotation?

Wed, 31st Mar 2021 12:57

* European shares up 0.2%

* Deliveroo flops on market debut

* DAX hovers around 15,000 points

* Eyes on Biden infrastructure plan

March 31 - Welcome to the home for real-time coverage of
markets brought to you by Reuters reporters. You can share your
thoughts with us at markets.research@thomsonreuters.com

TIME TO START SOME DEFENSIVE ROTATION? (1157 GMT)

It’s not easy to make the right choice in the stock markets,
amid cyclicals increasingly stretched valuations versus
defensives and expectations of stronger growth and inflation,
coupled with higher bond yields.

Morgan Stanley analysts see “potential catalysts for a
bigger tactical defensive rotation later in the year,” while
they are wary of “rotating too hard just yet.”

“Our expectation for continued strong growth data, prevents
us from wanting to get too defensive just yet, but we think it
makes sense to start to reduce the size of our underweight
stance,” they say in a research note.

Bottom line, they upgrade pharma stocks to neutral, which
they say trade “at a rare PE discount to the wider market,”
while downgrading to neutral consumer services and transport,
“where valuations look increasingly rich.”

BofA says cyclicals “are already pre-pricing an improvement
in macro momentum.”

But “if PMIs rebound to unusually strong levels by Q3 and
bond yields continue to rise, as we expect, this would imply a
further 15% upside for cyclicals versus defensives by Q3,” it
adds. In the table below BofA's forecast overview.

(Stefano Rebaudo)

*****

EUROPE: IN THE MOOD FOR LOVE (1130 GMT)

This has been a fine quarter for European equities which are
set to exit Q1 with a rise of over 8%.

Worth noting that for the first time since Q3 2019, the
STOXX 600 has outperformed the S&P 500 which is up 'only' 5.4%.

Europe, however, remains unloved, Barclays analysts point
out.

"Despite their good relative performance ytd, European
equities remain ignored by global investors", the bank's
analysts write.

"We believe that improving vaccine rollout later this year
and reopening could be the triggers for the region to see
inflows again", they argue, adding that because Europe is
overweight on popular value stocks, it could benefit from
managers rotating their portfolios.

(Julien Ponthus)

*****

NEW RECORD HIGH FOR AMSTERDAM (1018 GMT)

There's been a lot of chatter about the 15,000 points
snatched by the DAX but other indexes in Europe are also
enjoying the end of Q1.

Amsterdam's AEX has just reached a record high of 703.44
points, its highest level since September 2000!

The STOXX 600 is also very close to testing unchartered
highs, just 2 points below its February 2020 record of 433.90
points.

Here's the AEX since 1995:

(Julien Ponthus)

*****

DELIVEROO UNDERDELIVERS (0832 GMT)

Horrible, disastrous... there's no shortage of adjectives
out there to describe the fiasco of Deliveroo which a few
minutes after its London debut saw its shares hit a 271 pence
low, 30% below their 390 pence IPO price tag.

Here is a round up of comments we got so far.

Russ Mould, Investment Director at AJ Bell: "How could a
company that was valued at $3 billion in November, $5 billion in
January, be magically worth 8-9 billion in March - particularly
when according to its own statements it was potentially
requirement in need of emergency funding last year. I guess the
question now is does this mean that we’re about to enter a more
difficult period for these IPOs that loss-making companies
become with very high valuations, which would be an interesting
shift of tone".

Angelo Meda, portfolio manager at Banor SIM: "The wind has
turned on all growth stocks. I don't know if this is a stock
that will recover anytime soon. We stayed out of the IPO because
of concerns over valuation and regulation. Until there is
clarity on riders' rights it will be difficult to invest in this
sector".

Connor Campbell, analyst at Spreadex: "Deliveroo has been
able to grow to the point of launching on the stock market in
part thanks to the exploitation of its workers. Now, said
exploitation is one of the main reasons behind its sour start to
life as a public company, with multiple leading fund managers
expressing concern over its labour practices. It is maybe a case
of a perfectly zeitgeisty company in one sense – Deliveroo is a
primary pandemic beneficiary – coming of age in the wrong
moment, i.e. in the era of ostensible environmental, social and
corporate governance".

James Athey, investment director at Aberdeen Standard
Investments: "The number of institutions lining up to say no on
ESG grounds always looked like it was going to make it a tricky
debut".

Stephane Ekolo global equity strategist at Tradition: "It
stings. Some UK asset managers had warned about work conditions
and the business model and had flagged regulation risks".

Neil Wilson, analyst at Markets.com:
"Chiefly though it reflects the fact that even pricing the IPO
at the bottom of the range, Deliveroo was demanding too high a
price tag for a loss-making delivery platform in a very
competitive space with a questionable path to profitability. The
books were covered, it was just plain mis-priced".

(Julien Ponthus, Danilo Masoni, Elizabeth Howcroft)

*****

DAX RESISTS ABOVE 15K, DELIVEROO FLOPS (0726 GMT)

European shares are off to a muted start this morning with
the main regional benchmark trading just above parity and no
sector taking the lead in either direction.

Germany's DAX is flat but it's managing to hold above the
15,000 points mark it breached yesterday for the first time.

In London, Deliveroo delivered a disappointing debut,
falling as much as 30% from its IPO prices in the first minutes
of life.

Elsewhere, a couple of downgrades are making videogame maker
CD Projekt the biggest faller on the STOXX, down 11%.

Here's your snapshot.

(Danilo Masoni)

*****

SO LONG Q1, U.S. LEADS GOING INTO Q2 (0702 GMT)

The first quarter draws to a close and what a quarter it's
been: an 82 basis-point surge in U.S. Treasury yields on a
stimulus boost the size of which few would have anticipated, a
25% oil price jump, amateurs taking on seasoned hedge funds and
big banks taking big hits from trouble at hedge funds.

But having added some $2.6 trillion in value over the first
three months, MSCI's global equity index is ending the quarter
in a defensive mood. Asian stocks, outside Japan, are down 0.3%,
the Nikkei shed 0.9% and futures point to a weak open for
European bourses. Wall Street futures are flat.

The outlier is the dollar, riding at fresh one-year peaks
against the yen and at multi-month highs versus other major
currencies.

Its gains come as the United States races ahead of the rest
in terms of vaccinations, economic growth and the sheer size of
government spending. And U.S. President Joe Biden will outline
later on Wednesday how he intends to pay for a $3-$4 trillion
infrastructure plan.

That kind of spending will benefit the rest of the world
too; the IMF will raise global growth forecasts for 2021 and
2022, Managing Director Kristalina Georgieva said on Tuesday.

But the Biden plan, and the likelihood of more debt
issuance, also explains this week's bond selloff that's taken
10-year Treasury yields towards 14-months highs at around 1.78%.

In UK markets, trading starts in food delivery company
Deliveroo, whose shares will list at 390 pence each, valuing the
company at 7.6 billion pounds ($10.5 billion). It's the biggest
London IPO for a decade, yet its valuations lag continental
peers Just Eat and Delivery Hero.

Key developments that should provide more direction to
markets on Wednesday:

- Euro zone flash inflation data due; data on Tuesday showed
German inflation topped ECB target in March.

- China's manufacturing expands at the quickest pace in
three months in March.

- Britain's economy grows a stronger-than-expected 1.3% in
Q4.

- Hitachi to buy U.S. software firm GlobalLogic Inc for $9.6
billion.

- Germany to limit the use of AstraZeneca COVID-19
vaccine to people aged 60 and above

- OPEC+ oil producing group is concerned that uncertainties
may impact the recovery in oil demand

- Gold set for worst quarter since 2016.

- U.S. ADP national unemployment, Chicago PMI data due.

- Sweden's H&M swings to Q1 loss

(Dhara Ranasinghe)

*****

DELIVEROO FOR BREAKFAST (0625 GMT)

Today is Deliveroo day!

The food delivery company is making its debut on the London
stock market this morning in what is set to be the biggest IPO
since Glencore back in 2011.

Now, with the Nasdaq easing 0.1% yesterday and tech/growth
shares under pressure, the context is perhaps not ideal.

The S&P technology sector ended down 1% and was
the biggest drag on the S&P 500.

The Nasdaq is on track for its first monthly loss since
November with 10-year U.S. Treasury yields rising
to 1.77%, their highest since Jan. 22.

European futures are also in the red, losing about 0.3% at
the time of writing.

(Julien Ponthus)

*****

More News
25 Mar 2024 07:59

LONDON BRIEFING: AstraZeneca wins US approval, Kingfisher profit down

(Alliance News) - London's FTSE 100 is set to open lower on Monday, giving back some of last week's progress, when equities were boosted by hope of interest rate cuts.

Read more
25 Mar 2024 07:23

AstraZeneca gets FDA approval for Ultomiris treatment

(Sharecast News) - AstraZeneca has announced that its autoimmune disease treatment Ultomiris has been given the green light by US regulators.

Read more
21 Mar 2024 16:43

AstraZeneca's Tagrisso successful in treating lung cancer

(Alliance News) - AstraZeneca PLC on Thursday reported positive findings following a phase III trial of its lung cancer Tagrisso treatment.

Read more
19 Mar 2024 08:56

TOP NEWS: AstraZeneca to buy Fusion in deal worth over USD2 billion

(Alliance News) - AstraZeneca PLC on Tuesday said it will buy Fusion Pharmaceuticals Inc, a Canada-based clinical-stage biopharmaceutical company developing "next-generation" radioconjugates.

Read more
19 Mar 2024 07:05

AstraZeneca to buy US-listed Fusion Phrama for $2bn

(Sharecast News) - AstraZeneca said it had agreed to buy biopharmaceutical company Fusion Pharmaceuticals for up to $2bn.

Read more
18 Mar 2024 16:09

UK dividends calendar - next 7 days

Tuesday 19 March 
Jarvis Securities PLCdividend payment date
Wednesday 20 March 
Virgin Money UK PLCdividend payment date
Thursday 21 March 
abrdn Asia Focus PLCdividend payment date
abrdn Private Equity Opportunities Trust PLCex-dividend payment date
AIB Group PLCex-dividend payment date
Beazley PLCex-dividend payment date
BlackRock World Mining Trust PLCex-dividend payment date
British American Tobacco PLCex-dividend payment date
Chemring Group PLCex-dividend payment date
CLS Holdings PLCex-dividend payment date
Conduit Holdings Ltdex-dividend payment date
Craneware PLCex-dividend payment date
Crest Nicholson Holdings PLCex-dividend payment date
Diverse Income Trust PLCex-dividend payment date
Fonix Mobile PLCex-dividend payment date
FW Thorpe PLCex-dividend payment date
Glanbia PLCex-dividend payment date
GlobalData PLCex-dividend payment date
Globalworth Real Estate Investments Ltdex-dividend payment date
Goodwin PLCex-dividend payment date
Gore Street Energy Storage Fund PLCex-dividend payment date
Hargreaves Services PLCex-dividend payment date
HgCapital Trust PLCex-dividend payment date
Hikma Pharmaceuticals PLCex-dividend payment date
Jardine Matheson Holdings LDex-dividend payment date
London Finance & Investment Group PLCex-dividend payment date
Maven Income & Growth VCT 3 PLCex-dividend payment date
Maven Income & Growth VCT 5 PLCex-dividend payment date
MTI Wireless Edge Ltdex-dividend payment date
Nichols PLCex-dividend payment date
NWF Group PLCex-dividend payment date
Palace Capital PLCex-dividend payment date
Pearson PLCex-dividend payment date
Pembroke VCT B PLCex-dividend payment date
Primorus Investments PLCex-dividend payment date
Schroders PLCex-dividend payment date
Triple Point Energy Transition PLCex-dividend payment date
Tristel PLCex-dividend payment date
VPC Specialty Lending Investments PLCdividend payment date
Friday 22 March 
easyJet PLCdividend payment date
FRP Advisory Group PLCdividend payment date
Gulf Investment Fund PLCdividend payment date
Henderson Opportunities Trust PLCdividend payment date
Hercules Site Services PLCdividend payment date
Impax Asset Management Group PLCdividend payment date
JLEN Environmental Assets Group Ltddividend payment date
JPMorgan Multi-Asset Growth & Income PLCdividend payment date
Mattioli Woods PLCdividend payment date
Mobeus Income & Growth 2 VCT PLCdividend payment date
Mobeus Income & Growth 4 VCT PLCdividend payment date
Ramsdens Holdings PLCdividend payment date
Riverstone Credit Opportunities Income PLCdividend payment date
Ruffer Investment Co Ltddividend payment date
Samuel Heath & Sons PLCdividend payment date
Troy Income & Growth Trust PLCdividend payment date
Unilever PLCdividend payment date
Monday 25 March 
AstraZeneca PLCdividend payment date
Endeavour Mining PLCdividend payment date
Mountview Estates PLCdividend payment date
Shell PLCdividend payment date
  
Comments and questions to newsroom@alliancenews.com
  
A full 14-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
18 Mar 2024 14:08

AstraZenca hails Imfinzi and Lynparza results on endometrial cancer

(Alliance News) - AstraZeneca PLC on Monday reported positive findings following the analysis of results from a phase III probe of its Imfinzi and Lynparza cancer treatments.

Read more
14 Mar 2024 10:01

TOP NEWS: AstraZeneca buys France's Amolyt Pharma for USD1 billion

(Alliance News) - AstraZeneca PLC on Thursday said it has struck a deal to acquire Amolyt Pharma SAS, strengthening its late-stage rare disease pipeline.

Read more
14 Mar 2024 07:52

LONDON BRIEFING: Astra makes USD1.05 billion buy; Halma backs outlook

(Alliance News) - London's FTSE 100 is set to tread water after the opening bell sounds on Thursday, as investors look to a batch of US data to come in the early afternoon.

Read more
14 Mar 2024 07:16

AstraZeneca snaps up rare disease specialist Amolyt for $1.05bn

(Sharecast News) - Biopharma giant AstraZeneca has announced the acquisition of French biotech firm Amolyt Pharma for up to $1.05bn to beef up its late-stage rare disease pipeline.

Read more
8 Mar 2024 06:00

Astra, Sanofi's antibody 90% effective against RSV in infants - CDC

(Alliance News) - A new treatment for infant respiratory syncytial virus, RSV, – a leading cause of severe illness in US babies – is 90% effective in preventing hospitalization, health authorities said Thursday.

Read more
6 Mar 2024 14:40

UK BUDGET: Some tax cuts but vapes, tobacco and non-doms targeted

(Alliance News) - A cut to national insurance, stamp duty relief as well as a freeze on fuel and alcohol duties were among the marquee tax measures that UK Chancellor Jeremy Hunt announced in his budget on Wednesday.

Read more
5 Mar 2024 14:24

AstraZeneca's breast cancer treatment blocked for NHS use in England

(Alliance News) - A treatment that extends the life of people with advanced breast cancer has been blocked for NHS use in England in a move that potentially impacts thousands of patients.

Read more
4 Mar 2024 09:31

AstraZeneca and Daiichi Sankyo get EU approval for cancer treatment

(Alliance News) - AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday said that the European Medicines Agency has approved two marketing authorisation applications for their datopotamab deruxtecan in two types of cancer.

Read more
4 Mar 2024 07:18

AstraZeneca's chemo replacement treatment moves closer to EU approval

(Sharecast News) - European regulators have validated two marketing authorisation applications (MMAs) for AstraZeneca, as the biopharma giant's datopotamab deruxtecan chemotherapy replacement treatment comes one step closer to receiving the green light to treat two types of cancer.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.